Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4801884 | 0.87 | PTGS1 (0.36) | PTGS1PDE10ACDC7CDK2RAB9A | |
| SCHEMBL4804748 | 0.87 | PTGS1 (0.39) | PTGS1PDE10ACDC7CDK2RAB9A | |
| SCHEMBL4810556 | 0.86 | PTGS1 (0.37) | PTGS1PDE10ACDC7CDK2RAB9A | |
| SCHEMBL4810377 | 0.86 | CYP2A6 (0.40) | PTGS1PDE10ACDC7CDK2RAB9A | |
| SCHEMBL4861340 | 0.85 | CRHR1 (0.39) | PTGS1RAB9APTGS2CRHR1 | |
| SCHEMBL4869299 | 0.85 | PTGS1 (0.38) | PTGS1PDE10ACDC7CDK2RAB9A | |
| SCHEMBL4873661 | 0.85 | PTGS1 (0.35) | PTGS1PDE10ACDC7CDK2RAB9A | |
| SCHEMBL4869383 | 0.83 | ADRB2 (0.48) | PTGS1PDE10ACDC7CDK2PTGS2 | |
| SCHEMBL4869334 | 0.82 | MAPT (0.40) | PTGS1PDE10APTGS2CRHR1 | |
| SCHEMBL4878008 | 0.82 | MAPT (0.34) | PTGS1PDE10ACRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER INC | 2008-04-17 | — | — | US | claimed |
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER INC | 2008-04-17 | — | — | US | disclosed |
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER INC | 2008-04-17 | — | — | US | disclosed |
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER INC | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PDE5A, PDE3B, PDE12 | PTGS1 527/4885PDE10A 8/4885CDC7 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.